Literature DB >> 28470435

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28470435     DOI： 10.1007/s00417-017-3681-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Authors:  Yuichiro Ogura; Johann Roider; Jean-François Korobelnik; Frank G Holz; Christian Simader; Ursula Schmidt-Erfurth; Robert Vitti; Alyson J Berliner; Florian Hiemeyer; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink
Journal:  Am J Ophthalmol       Date:  2014-07-25       Impact factor: 5.258

2.  Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.

Authors:  Sylvie Julien; Antje Biesemeier; Tatjana Taubitz; Ulrich Schraermeyer
Journal:  Br J Ophthalmol       Date:  2014-01-23       Impact factor: 4.638

Review 3.  TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.

Authors:  K Bailey Freund; Jean-François Korobelnik; Robert Devenyi; Carsten Framme; John Galic; Edward Herbert; Hans Hoerauf; Paolo Lanzetta; Stephan Michels; Paul Mitchell; Jordi Monés; Carl Regillo; Ramin Tadayoni; James Talks; Sebastian Wolf
Journal:  Retina       Date:  2015-08       Impact factor: 4.256

4.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

5.  Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

Authors:  Irini Chatziralli; George Theodossiadis; Marilita M Moschos; Panagiotis Mitropoulos; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-18       Impact factor: 3.117

6.  Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Authors:  Jeffrey S Heier; W Lloyd Clark; David S Boyer; David M Brown; Robert Vitti; Alyson J Berliner; Husain Kazmi; Yu Ma; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; Julia A Haller
Journal:  Ophthalmology       Date:  2014-03-27       Impact factor: 12.079

7.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Authors:  Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2011-06-29       Impact factor: 12.079

8.  Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.

Authors:  Magda Gharbiya; Filippo Cruciani; Cesare Mariotti; Francesca Grandinetti; Marco Marenco; Vittorio Cacace
Journal:  J Ocul Pharmacol Ther       Date:  2015-06-03       Impact factor: 2.671

9.  Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).

Authors:  Sandeep Grover; Ravi K Murthy; Vikram S Brar; Kakarla V Chalam
Journal:  Am J Ophthalmol       Date:  2009-05-09       Impact factor: 5.258

10.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors:  Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal:  Angiogenesis       Date:  2012-06       Impact factor: 9.596
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.